Skip to main content

Table 2 Assessment of radiographic progression in psoriatic arthritis trials

From: Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

StudyScoring methodRadiographic assessment time point, weekMean change in radiographic score at week 24Proportion of patients with no progression (mean change ≤ 0.5) at week 24, %
PlaceboActive treatmentPlaceboActive treatment
Etanercept vs placebo (phase 3) [15, 16]Sharp24 and 481.0a− 0.03a8.6a,b33.8a,b
ADEPT (adalimumab vs placebo) [17, 18]Sharp241.0− 0.271.191.0
IMPACT (infliximab vs placebo) [19]SvdH50− 1.95 (PBO/infliximab)c− 1.52c84.8 (PBO/infliximab)c83.8c
IMPACT 2 (infliximab vs placebo) [20]SvdH24 and 540.82− 0.7078.090.0
GO-REVEAL (golimumab vs placebo) [21]SvdH24 and 520.27− 0.0962.7b77.7b
GO-VIBRANT (golimumab vs placebo) [22]SvdH242.0− 0.443.0b71.7b
RAPID-PsA (certolizumab pegol) [23, 24]SvdH12 and 240.280.06 (200 mg Q2W + 400 mg Q4W)80.193.5 (200 mg Q2W); 90.4 (400 mg Q4W)
PSUMMIT-1 and -2 (ustekinumab vs placebo) [25]SvdH24 and 521.00.459.8b66.5b
FUTURE 1 (secukinumab vs placebo) [26]SvdH16 or 24 and 520.570.08 (pooled secukinumab group)75.782.3 (IV → 150 mg); 92.3 (IV → 75 mg)
FUTURE 5 (secukinumab vs placebo) [27]SvdH240.50.08 (300 mg + LD); 0.17 (150 mg + LD); − 0.09 (150 mg − LD)73.688.0.(300 mg + LD); 79.8 (150 mg + LD); 83.8 (150 mg − LD)
SPIRIT-P1 (ixekizumab vs placebo vs adalimumab) [28]SvdH24 and 520.27 (PBO/IXEQ4W)d; 0.41 (PBO/IXEQ2W)d0.54 (IXEQ4W/IXEQ4W)d; 0.09 (IXEQ2W/IXEQ2W)d; 0.32 (ADA/IXEQ4W)d; − 0.03 (ADA/IXEQ2W)d94.1 (PBO/IXEQ4W)d; 65.7 (PBO/IXEQ2W)d88.9 (IXEQ4W/IXEQ4W)d; 90.4 (IXEQ2W/IXEQ2W)d; 87.5 (ADA/IXEQ4W)d; 91.4 (ADA/IXEQ2W)d
ASTRAEA (abatacept vs placebo) [29]SvdH24 and 520.350.3032.7b42.7b
OPAL Broaden (tofacitinib vs adalimumab vs placebo) [30]SvdH12 monthsNot reported by treatment arm.
Range of change from baseline, − 0.07 to 0.09a
95.8 (PBO/TOFA 5 mg)a; 91.1 (PBO/TOFA 10 mg)a95.9 (TOFA 5 mg)a; 94.9 (TOFA 10 mg)a; 97.9 (ADA)a
SEAM-PsA (methotrexate vs etanercept vs combination) [31]SvdH24 and 480.08 (MTX)e; − 0.04 (ETN)e; − 0.01 (MTX + ETN)e89.4 (MTX)b,e; 94.7 (ETN)b,e; 94.7 (MTX + ETN)b,e
  1. ADA adalimumab, ETN etanercept, IXE ixekizumab, LD loading dose, MTX methotrexate, PBO placebo, PsA psoriatic arthritis, Q2W every 2 weeks, Q4W every 4 weeks, SvdH modified Sharp-van der Heijde score for PsA, TOFA tofacitinib
  2. aMean change from baseline at 12 months
  3. bNo progression was defined as a mean change of ≤ 0 from baseline
  4. cMean change from baseline at week 50
  5. dMean change from baseline at week 52
  6. eMean change from baseline at week 48
\